Search Results
Your search for The ASCO Post Staff ,The ASCO Post Staff matches 6181 pages
Showing 1401 - 1450Israeli Surgical Oncology Leader Dov Zippel, MD, Considers the Evolving Landscape of Cancer Care in a Small Nation
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Dov Zippel, MD, a surgical oncologist at Sheba Medical Center in Tel Hashomer, Israel, where he is Head of the Meirav Breast Center. Dr. Zippel is the current President of ...
BCG Vaccines May Provide Protective Effect Against Alzheimer's Disease
Researchers have found that patients treated with the Bacillus Calmette-Guérin (BCG) vaccine may have a reduced risk of Alzheimer’s disease and related dementias, according to a novel study published by Weinberg et al in JAMA Network Open. Background The BCG vaccine has been known to offer multiple ...
Partnering With Patients: The Cornerstone of Cancer Care and Research
The health and well-being of our clinicians, our communities, and our care systems need vigilance now more than ever to ensure we keep pace with the effects of change that is also advancing our medicine. When clinicians or patients talk about health care, they might mention frustrations with forms ...
Study Analyzes Relationship Between Cancer Survivors’ Tobacco Use, Symptom Burden, and Motivation to Quit Smoking
Investigators have found that current smoking and vaping may be associated with a higher burden of symptoms among adult cancer survivors but that these symptoms may not have had an impact on the desire to quit smoking. The new study was published by Price et al in Cancer. Background Continued...
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory B-Cell Lymphoma
On May 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the bispecific CD20-directed CD3 T-cell engager epcoritamab-bysp (Epkinly) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from...
Association Between Overweight/Obesity and Risk of Gastrointestinal Cancer
Researchers have found that individuals in early and middle adulthood who have a body mass index (BMI) indicating that they have overweight or obesity may be at an increased risk of developing gastrointestinal cancer, according to a new study published by Loomans-Kropp and Umar in JAMA Network...
Cancer-Specific Mortality Rates Vary Widely Across the Globe, Study Finds
Investigators have found that in the majority of countries studied, the recent mortality rates for all major cancer types have decreased except for lung cancer among female patients and hepatic cancer among male patients—where increasing rates were observed in most countries, according to a novel...
Patients With Cervical Cancer May Be at Higher Risk for Urinary Tract Infections After Radical Hysterectomies
Patients with early-stage cervical cancer may have an increased risk of developing catheter-associated urinary tract infections following radical hysterectomies if they had a history of smoking or used catheters for more than 7 days postsurgery, according to a new study by Mercadel et al in the...
HPV Self-Collection Kits May Increase Cervical Cancer Screenings Among Underscreened, Underserved Patients
Researchers have found that mailing human papillomavirus (HPV) self-collection kits in addition to offering scheduling assistance to underscreened, underserved patients may increase the rate of cervical cancer screenings compared with scheduling assistance alone, according to a new study published...
Combined Delivery of DNX-2401 Plus Pembrolizumab May Be Safe and Effective in Patients With Recurrent Glioblastoma
Intratumoral delivery of the engineered oncolytic virus DNX-2401 in combination with subsequent immunotherapy with pembrolizumab may be safe and effective at improving survival outcomes in patients with recurrent glioblastoma, according to a study published by Nassiri et al in Nature Medicine....
Phase II Trial of Guadecitabine Plus Atezolizumab in Patients With Metastatic Bladder Cancer
Although hypomethylating agents previously appeared to be a promising treatment option for patients with bladder cancer refractory to immunotherapy, researchers were forced to halt a recent phase II clinical trial after patients experienced either no response to treatment or rapid tumor...
Patients With Cancer May Prefer Telemedicine Appointments Over In-Person Visits When Both Are Available
Investigators have found that telemedicine may consistently outperform in-person visits for cancer care when assessed for access to care, provider response, and patient experience, according to a new study published by Patel et al in JNCCN–Journal of the National Comprehensive Cancer Network....
Immigrant Adults With Hepatocellular Carcinoma May Have Higher Survival Rates Than Those Born in the United States
Immigrant adult patients who have hepatocellular carcinoma and reside in the United States may have higher rates of survival compared with those who have the disease and were born in the United States, according to a new study published by Zhou et al in the Journal of the National Cancer Institute. ...
President Biden Announces Intent to Nominate Monica M. Bertagnolli, MD, as Director of the NIH
In a statement released by The White House on May 15, President Joe Biden announced his intent to nominate Monica M. Bertagnolli, MD, as Director of the National Institutes of Health (NIH), the world’s preeminent biomedical research organization. As the statement makes clear, Dr. Bertagnolli is a...
Young Native Hawaiians and Pacific Islanders May Face Highest Rates of Cancer Mortality
Investigators have found that young Native Hawaiian and Pacific Islander patients may experience the highest rates of cancer mortality of any racial group in the United States among those aged 20 to 49 years. The new data were published by Haque et al in the Journal of the National Cancer...
Cabozantinib in Combination With Nivolumab and Ipilimumab May Slow Progression of Advanced Renal Cell Carcinoma
The targeted kinase inhibitor cabozantinib plus a two-drug immunotherapy combination of nivolumab and ipilimumab may be capable of slowing cancer progression in patients with advanced renal cell carcinoma who received no prior lines of therapy, according to a study published by Choueiri et al in...
Adding Azacitidine to Standard Chemotherapy May Be Effective for Patients With PTCL-TFH
Researchers have found that azacitidine may be capable of increasing the effectiveness of chemotherapy and aiding nearly 90% of patients who had peripheral T-cell lymphoma with the T follicular helper cell phenotype (PTCL-TFH) achieve remission, according to a novel study published by Ruan et al in ...
Racial Disparities in the Risk of Ovarian Cancer for Patients With Fibroids and Endometriosis
A case-control study published recently by Harris et al in Obstetrics & Gynecology evaluated associations between endometriosis, uterine leiomyomas, and ovarian cancer risk by race, as well as the impact of hysterectomy on these associations. The investigators found that hysterectomy may modify ...
Novel Calculator May Identify Patients With Favorable-Prognosis Hematologic Cancers
Researchers have developed a calculator that may be capable of identifying patients who have multiple myeloma and light-chain amyloidosis with more benign profiles and, consequently, better prognoses, according to a novel study published by Burgos et al in the Journal of Clinical Oncology. The...
New Breast Cancer Screening Guidelines Call for Earlier, More Intensive Screenings for Women at High Risk
Updated recommendations from the American College of Radiology encouraged all women—particularly Black women and Ashkenazi Jewish women—to undergo risk assessments at 25 years of age to determine whether they may need breast cancer screenings earlier than age 40, according to new guidelines...
Prognostic Factors Associated With Survival in Platinum-Resistant Ovarian Cancer
Overall survival time was doubled in women with recurrent platinum-resistant ovarian cancer who have BRCA1/2 mutations, who were treated with PARP inhibitors, and whose tumors were homologous repair–deficient (HRD-test–positive), according to a study that examined prognostic factors for survival in ...
Novel Immunotherapy Combination Explored in Platinum-Resistant Ovarian Cancer
Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with platinum-resistant or -refractory ovarian cancer, in the ongoing phase Ib C-800 study presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Bruno...
ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer
Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...
Expert Point of View: Carol Aghajanian, MD
Carol Aghajanian, MD, Chief of the Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer Center, New York, commented on the final analysis of NOVA for The ASCO Post. She highlighted the difficulty in truly measuring overall survival in recurrent ovarian cancer. Dr. Aghajanian also ...
NOVA: Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer
After resolving missing survival data in the phase III ENGOT-OV16/NOVA trial, no statistically significant difference in overall survival was found for patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the PARP inhibitor niraparib, investigators...
Expert Point of View: Amanda Nickles Fader, MD
Amanda Nickles Fader, MD, Professor of Gynecology and Obstetrics, Professor of Oncology, and Vice Chair of Gynecologic Surgical Operations at Johns Hopkins Health System, Baltimore, provided her thoughts on GOG 3026 for The ASCO Post. Dr. Fader applauded the investigators and the Gynecologic...
GOG 3026: Durable Responses With Ribociclib Plus Letrozole in Low-Grade Serous Ovarian Cancer
In patients with recurrent low-grade serous ovarian cancer, treatment with ribociclib plus letrozole was not only active, but led to outcomes that are comparable to those achieved with current agents—with a particularly striking 19-month duration of response—according to Brian M. Slomovitz, MD,...
SGO Presentations Explore Inequitable Access to Clinical Trials and Its Impact on Survival
Two studies presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer underscore the importance of enrolling patients with gynecologic cancer on clinical trials and of assuring trial access to racial minorities. One study found a statistically significant...
Expert Point of View: Joshua G. Cohen, MD
Joshua G. Cohen, MD, Associate Clinical Professor in the Department of Surgery and Medical Director of the Orange County Gynecologic Cancer Program at City of Hope, Orange County, California, shared his thoughts on the ADAGIO trial with The ASCO Post. He noted that uterine serous carcinoma—the...
Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma
The oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated by more than half the patients with recurrent or persistent uterine serous carcinoma in the phase IIb ADAGIO trial. The findings were reported at the Society of Gynecologic Oncology (SGO) 2023...
City of Hope Appoints New Director and Chief Scientific Officer
City of Hope recently announced the appointment of John D. Carpten, PhD, as Director of the National Cancer Institute (NCI)-designated comprehensive cancer center, Director of Beckman Research Institute of City of Hope, and Chief Scientific Officer. Dr. Carpten will also hold the Irell &...
AACR Announces Fellows of the AACR Academy Class of 2023
The American Association for Cancer Research (AACR) recently announced its newly elected class of Fellows of the AACR Academy. Fellows of the AACR Academy serve as a global brain trust of top contributors to cancer science and medicine who help advance the mission of the AACR to prevent and cure...
Olivier Delattre, MD, PhD, Honored With 2023 AACR–St. Baldrick’s Foundation Award
The American Association for Cancer Research (AACR) presented Olivier Delattre, MD, PhD, with the 2023 AACR–St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research during the AACR Annual Meeting 2023 in April in Orlando, Florida. Dr. Delattre is Director of the...
USPSTF Issues Draft Recommendation Statement on Screening for Breast Cancer: All Women Should Be Screened Every Other Year, Beginning at Age 40
On May 9, the U.S. Preventive Services Task Force (USPSTF) posted a draft recommendation statement on screening for breast cancer. The USPSTF now recommends that all women get screened for breast cancer every other year starting at age 40 years (this is a B grade recommendation, meaning the USPSTF...
Marcus O. Butler, MD, on Uveal Melanoma: Tebentafusp and Evidence of Tumor Response
Marcus O. Butler, MD, of Toronto’s Princess Margaret Cancer Centre, discusses evidence of tumor response in orbital lesions treated with tebentafusp in patients with metastatic uveal melanoma. Tebentafusp is a first-in-class novel bispecific protein, the first therapy to show superior overall...
Bariatric Surgery May Reduce Risk of Obesity-Related Cancers by More Than Half
Researchers have found that patients who are obese and undergo bariatric surgery may have a greater than 50% decreased incidence rate of obesity-related cancer compared with patients who did not have the weight-loss procedure, according to new findings presented by Chittajalu et al at Digestive...
Three New Studies Unveil Recent Developments in the Screening and Treatment of Biliary Tract Cancer and Colorectal Cancer
Researchers have revealed the impacts of several new developments in screening and treating patients with biliary tract cancer and colorectal cancer—including the development of patient-derived organoids to test chemotherapy response, the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to...
Mansoor R. Mirza, MD, on Endometrial Cancer: New Findings on Dostarlimab-gxly Plus Chemotherapy
Mansoor R. Mirza, MD, of Copenhagen’s Rigshospitalet, discusses phase III data from the ENGOT-EN6-NSGO/GOG-3031/RUBY study, which showed that, compared with carboplatin and paclitaxel alone, dostarlimab-gxly plus carboplatin and paclitaxel increased progression-free survival in patients with...
Enrollment Criteria for Multiple Myeloma Clinical Trials May Exclude Patients From Racial and Ethnic Minorities
The parameters set to determine which patients can enroll in clinical trials testing new multiple myeloma treatments may disproportionately exclude patients from racial and ethnic minority groups, according to a new study published by Kanapuru et al in the journal Blood. Background Multiple myeloma ...
Antibacterial Treatment May Resolve Acute Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
Researchers have found that acute radiation dermatitis may involve the skin bacterium Staphylococcus aureus and that a simple, low-cost treatment may prevent severe cases in patients undergoing radiation therapy, according to two novel studies published by Kost et al—one a randomized clinical trial ...
Newly Identified Risk Factors May Point to a Heightened Risk for Early-Onset Colorectal Cancer Among Younger Adult Patients
Researchers have identified four warning signs and symptoms that may indicate an elevated risk of early-onset colorectal cancer, according to a new study published by Fritz et al in the Journal of the National Cancer Institute. The findings may be key to helping physicians more effectively detect...
Novel AI Model Offers Potential for Earlier Lung Cancer Diagnoses
A new artificial intelligence (AI) model could help physicians diagnose lung cancer earlier, according to a study published by Hunter et al in eBioMedicine. The findings suggested that the new model may yield a diagnosis more quickly and potentially more accurately than two existing risk assessment ...
Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Niraparib From the ENGOT-OV16/NOVA Trial
Ursula A. Matulonis, MD, of Dana-Farber Cancer Center discusses the ENGOT-OV16/NOVA study, which initially showed that niraparib maintenance therapy significantly prolonged progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of germline BRCA mutation...
Anita Mamtani, MD, on Axillary Dissection: For What Types of Breast Cancer Can It Be Avoided?
Anita Mamtani, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings showing that axillary lymph node dissection was required by less than 2% of patients with cT1NO triple-negative or HER2-positive breast cancer having upfront surgery. There was no clear advantage of neoadjuvant...
Kari M. Rosenkranz, MD, on Breast Cancer: Impact of Breast Conservation on Local Recurrence
Kari M. Rosenkranz, MD, of Dartmouth Health, discusses findings from the ACOSOG Z11102 (Alliance) study, which showed that breast-conserving therapy is safe for patients with multiple ipsilateral breast cancer lesions, resulting in low recurrence rates. However, omitting adjuvant endocrine therapy...
Judy C. Boughey, MD, on Changes in Axillary Surgical Management: An I-SPY2 Analysis
Judy C. Boughey, MD, of the Mayo Clinic, discusses the decrease, over the past decade, of axillary lymph node dissection, especially in patients with node-positive breast cancer at diagnosis who had sentinel lymph node surgery after neoadjuvant chemotherapy. These findings are based on the records...
Novel Imaging Agent May Help Surgeons Detect Residual Tumor Tissue Following Breast-Conserving Surgery
Researchers have discovered that the investigational optical imaging agent pegulicianine in fluorescence-guided surgery (pFGS) may have been effective at helping surgeons identify and remove residual tumor tissue in patients with breast cancer during breast-conserving surgery, according to a novel...
Economic Hardship May Be Predictive of Neurocognitive Outcomes in Pediatric Patients Undergoing Radiation Therapy
Researchers have found that pediatric patients with cancer undergoing radiation therapy may experience greater baseline and long-term neurocognitive outcomes when they have supportive environments compared with those who live in neighborhoods with economic hardship, according to a new study...
Lifestyle Habits, Risk Factors, and Cancer Screening During COVID-19 Pandemic
Investigators discovered both favorable and unfavorable changes in major cancer risk factors, preventive behaviors and services, and screenings in the United States during the COVID-19 pandemic, according to a new study published by Star et al in Cancer Epidemiology, Biomarkers & Prevention....
AI-Based Decision Support Systems for Mammography
Incorrect advice offered by an artificial intelligence (AI)-based decision support system could impair the performance of radiologists at every level of expertise when reading mammograms, according to a new study published by Dratsch et al in Radiology. Background Often touted as a “second set of...
